High-Throughput Generation of Monoclonal Anti-Peptide Antibodies for High Sensitivity Targeted MS Analysis of Biomarker Candidates


To develop new technologies for biomarker verification and conduct initial validation of prostate cancer biomarker candidates

Anticipated Impact: 

Accelerated translation of biomarker candidates into commercial assays for the diagnosis and monitoring of prostate cancer and other major diseases


The use of powerful proteomics technologies has resulted in the identification of hundreds of proteins that could serve as biomarkers for diagnosis and monitoring of cancer and other major diseases. Unfortunately, the translation of this work into clinical assays has been slowed by the lack of methodologies for rapid validation of large numbers of biomarker candidates in biological specimens. This study will develop novel technologies for sensitive, high-throughput verification of biomarker candidates and then use these technologies for the initial validation of candidates isolated from men with prostate cancer. If successful, these technologies could be generally applicable to the analysis of biomarker candidates for multiple diseases, thus facilitating the transition of those biomarkers into commercial assays. This work could also potentially lead to new assays for prostate cancer diagnosis and prognostication.

Prostate Cancer Detection, Biomarkers, Targeted Therapy

Grant Update

Principal Investigator:
Adrian Ozinsky
Grantee Organization:
Institute for Systems Biology
Grant Title:
High-throughput generation of monoclonal anti-peptide antibodies for high sensitivity targeted MS analysis of biomarker candidates
Grant Cohort and Year:
2009 Project Grant (01)
Grant Period:
02/03/2010 - 03/31/2013 (Completed)
Grant Amount:
We were successful in generating antibodies that target peptides derived from prostate cancer biomarkers. We intend using this purification method to improve the sensitivity of biomarker assays performed by mass spectrometry. We have applied for funding to assess the feasibility of scale-up of this work, to address additional biomarkers, and towards the possibility of selling these reagents as diagnostic assays.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact

Legislative Districts:
11, 34, 36, 37, 43, 46

Health Impacts

Prostate Cancer Detection, Biomarkers, Targeted Therapy